S N M Schoonenboom

Summary

Affiliation: VU University Medical Center
Country: The Netherlands

Publications

  1. doi request reprint Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort
    N S M Schoonenboom
    Departments of Neurology, VU University Medical Center, Alzheimer Center, Amsterdam, The Netherlands
    Neurology 78:47-54. 2012
  2. ncbi request reprint Amyloid beta 38, 40, and 42 species in cerebrospinal fluid: more of the same?
    Niki S Schoonenboom
    Alzheimer Center and Department of Neurology, VU University Medical Center, Amsterdam, The Netherlands
    Ann Neurol 58:139-42. 2005
  3. ncbi request reprint Differences and similarities between two frequently used assays for amyloid beta 42 in cerebrospinal fluid
    Niki S M Schoonenboom
    Alzheimer Center and Department of Neurology, VU University Medical Center, Amsterdam, The Netherlands
    Clin Chem 51:1057-60. 2005
  4. ncbi request reprint Biomarker profiles and their relation to clinical variables in mild cognitive impairment
    S N M Schoonenboom
    Department of Neurology Alzheimer Centre, VU University Medical Centre, Amsterdam, The Netherlands
    Neurocase 11:8-13. 2005
  5. ncbi request reprint Effects of processing and storage conditions on amyloid beta (1-42) and tau concentrations in cerebrospinal fluid: implications for use in clinical practice
    Niki S M Schoonenboom
    Alzheimer Center and Department of Neurology, VU University Medical Center, 1081 HV Amsterdam, The Netherlands
    Clin Chem 51:189-95. 2005
  6. ncbi request reprint Amyloid beta(1-42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease
    N S M Schoonenboom
    Alzheimer Center, Department of Neurology, VU University Medical Center, Amsterdam, The Netherlands
    Neurology 62:1580-4. 2004
  7. ncbi request reprint CSF and MRI markers independently contribute to the diagnosis of Alzheimer's disease
    Niki S M Schoonenboom
    Department of Neurology, Alzheimer Center, VU University Medical Center, 1081 HV Amsterdam, The Netherlands
    Neurobiol Aging 29:669-75. 2008
  8. pmc CSF biomarkers in frontotemporal lobar degeneration: relations with clinical characteristics, apolipoprotein E genotype, and neuroimaging
    Y A L Pijnenburg
    Alzheimer Center, Department of Neurology, VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands
    J Neurol Neurosurg Psychiatry 77:246-8. 2006
  9. ncbi request reprint CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment
    F H Bouwman
    Department of Neurology, Alzheimer Centre, VU Medical Center, MB Amsterdam, The Netherlands
    Neurobiol Aging 28:1070-4. 2007
  10. doi request reprint Distribution of APOE genotypes in a memory clinic cohort
    W M van der Flier
    Alzheimer Center, Department of Neurology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands
    Dement Geriatr Cogn Disord 25:433-8. 2008

Collaborators

Detail Information

Publications20

  1. doi request reprint Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort
    N S M Schoonenboom
    Departments of Neurology, VU University Medical Center, Alzheimer Center, Amsterdam, The Netherlands
    Neurology 78:47-54. 2012
    ..To determine how amyloid β 42 (Aβ42), total tau (t-tau), and phosphorylated tau (p-tau) levels in CSF behave in a large cohort of patients with different types of dementia...
  2. ncbi request reprint Amyloid beta 38, 40, and 42 species in cerebrospinal fluid: more of the same?
    Niki S Schoonenboom
    Alzheimer Center and Department of Neurology, VU University Medical Center, Amsterdam, The Netherlands
    Ann Neurol 58:139-42. 2005
    ..All three Abeta peptides were interrelated, particularly CSF Abeta38 and Abeta40. Diagnostic accuracy of CSF Abeta42 concentrations was not improved by applying the ratios of CSF Abeta42 to Abeta38 or Abeta40...
  3. ncbi request reprint Differences and similarities between two frequently used assays for amyloid beta 42 in cerebrospinal fluid
    Niki S M Schoonenboom
    Alzheimer Center and Department of Neurology, VU University Medical Center, Amsterdam, The Netherlands
    Clin Chem 51:1057-60. 2005
  4. ncbi request reprint Biomarker profiles and their relation to clinical variables in mild cognitive impairment
    S N M Schoonenboom
    Department of Neurology Alzheimer Centre, VU University Medical Centre, Amsterdam, The Netherlands
    Neurocase 11:8-13. 2005
    ..These correlations suggest that the biomarkers are not independent when compared to the other AD markers. Longitudinal studies are necessary to interpret the correlations between biomarkers, imaging, and neuropsychological markers...
  5. ncbi request reprint Effects of processing and storage conditions on amyloid beta (1-42) and tau concentrations in cerebrospinal fluid: implications for use in clinical practice
    Niki S M Schoonenboom
    Alzheimer Center and Department of Neurology, VU University Medical Center, 1081 HV Amsterdam, The Netherlands
    Clin Chem 51:189-95. 2005
    ..We investigated the effects of storage temperature, repeated freeze/thaw cycles, and centrifugation on the concentrations of A beta 42 and tau in CSF...
  6. ncbi request reprint Amyloid beta(1-42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease
    N S M Schoonenboom
    Alzheimer Center, Department of Neurology, VU University Medical Center, Amsterdam, The Netherlands
    Neurology 62:1580-4. 2004
    ..To determine the diagnostic value of CSF amyloid beta(1-42) (Abeta42), CSF total tau, and CSF tau phosphorylated at threonine-181 (Ptau-181) in early-onset Alzheimer disease (EAD) vs frontotemporal lobar degeneration (FTLD)...
  7. ncbi request reprint CSF and MRI markers independently contribute to the diagnosis of Alzheimer's disease
    Niki S M Schoonenboom
    Department of Neurology, Alzheimer Center, VU University Medical Center, 1081 HV Amsterdam, The Netherlands
    Neurobiol Aging 29:669-75. 2008
    ..Atrophy of the medial temporal lobe (MTA) on magnetic resonance imaging (MRI) reflects neuronal loss in this area...
  8. pmc CSF biomarkers in frontotemporal lobar degeneration: relations with clinical characteristics, apolipoprotein E genotype, and neuroimaging
    Y A L Pijnenburg
    Alzheimer Center, Department of Neurology, VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands
    J Neurol Neurosurg Psychiatry 77:246-8. 2006
    ..CSF Abeta42 variability remained unexplained. Future research could study the role of ApoE genotype and Abeta42 in FTLD, as well as establish measures for disease intensity...
  9. ncbi request reprint CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment
    F H Bouwman
    Department of Neurology, Alzheimer Centre, VU Medical Center, MB Amsterdam, The Netherlands
    Neurobiol Aging 28:1070-4. 2007
    ..To study CSF biomarkers, beta-amyloid(1-42) (Abeta(1-42)) and tau, and medial temporal lobe atrophy (MTA) on MRI in their ability to predict dementia in patients with mild cognitive impairment (MCI)...
  10. doi request reprint Distribution of APOE genotypes in a memory clinic cohort
    W M van der Flier
    Alzheimer Center, Department of Neurology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands
    Dement Geriatr Cogn Disord 25:433-8. 2008
    ..To describe the distribution of apolipoprotein E (APOE) genotypes in a cohort of memory clinic patients...
  11. pmc Decreased cerebrospinal fluid amyloid beta (1-40) levels in frontotemporal lobar degeneration
    Y A L Pijnenburg
    Alzheimer Centre and Department of Neurology, VU University Medical Centre, PO Box 7057, 1007 MB Amsterdam, The Netherlands
    J Neurol Neurosurg Psychiatry 78:735-7. 2007
    ..These findings favour a differential involvement of amyloid beta peptides in FTLD compared with AD...
  12. ncbi request reprint CSF markers related to pathogenetic mechanisms in Alzheimer's disease
    C Mulder
    Department of Clinical Chemistry, Research Institute Neurosciences, VU University Medical Center, 1007 MB Amsterdam, The Netherlands
    J Neural Transm 109:1491-8. 2002
    ..Therefore, in our opinion these factors can be excluded from the list of potentially interesting biomarkers for AD diagnosis and progression...
  13. ncbi request reprint Total tau and phosphorylated tau 181 levels in the cerebrospinal fluid of patients with frontotemporal dementia due to P301L and G272V tau mutations
    Sonia M Rosso
    Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands
    Arch Neurol 60:1209-13. 2003
    ..Mutations in the tau gene have been found in the familial form of FTD, linked to chromosome 17q21-22, showing a spectrum of tauopathy...
  14. ncbi request reprint The effect of APOE genotype on clinical phenotype in Alzheimer disease
    W M van der Flier
    Department of Neurology and Alzheimer Center, Vrije Universiteit Medical Center, PO Box 7057, 1007 MB Amsterdam, The Netherlands
    Neurology 67:526-7. 2006
    ..2 to 7.8), suggesting that two subtypes of AD can be identified. The typical amnestic phenotype seems to be promoted by the APOE-epsilon4 allele, whereas the atypical nonmemory phenotype occurs in the absence of the APOE-epsilon4 allele...
  15. ncbi request reprint CSF neurofilaments in frontotemporal dementia compared with early onset Alzheimer's disease and controls
    Yolande A L Pijnenburg
    Department of Neurology, Alzheimer Center, VU University Medical Center, Amsterdam, The Netherlands, and Chelsea and Westminster, Brompton and Charing Cross Hospitals, London, UK
    Dement Geriatr Cogn Disord 23:225-30. 2007
    ....
  16. ncbi request reprint The transmethylation cycle in the brain of Alzheimer patients
    Cees Mulder
    Department of Clinical Chemistry, VU University Medical Center, P O Box 7057, 1007 MB Amsterdam, The Netherlands
    Neurosci Lett 386:69-71. 2005
    ..We found no statistical differences between AD patients and controls for 5-MTHF, SAM and SAH levels, and the SAM/SAH-ratio in CSF. These findings argue against a possible change in methylation of the promoter and expression of PS1...
  17. doi request reprint Inflammatory markers in AD and MCI patients with different biomarker profiles
    Alie Schuitemaker
    Department of Neurology Alzheimer Center, VU University Medical Center, 1007 MB Amsterdam, The Netherlands
    Neurobiol Aging 30:1885-9. 2009
    ..The aim of this study was to demonstrate the involvement of the inflammatory proteins IL-6, ACT and CRP early in the pathology process of AD in patients with mild cognitive impairment (MCI) and AD...
  18. doi request reprint CSF biomarker levels in early and late onset Alzheimer's disease
    Femke H Bouwman
    Alzheimer Center and Department of Neurology, VU University Medical Center, Amsterdam, The Netherlands
    Neurobiol Aging 30:1895-901. 2009
    ..To compare CSF levels of beta-amyloid 1-42 (Abeta(1-42)), total tau (tau) and tau phosphorylated at threonine 181 (ptau-181) between AD patients and controls according to age...
  19. pmc Functional brain connectivity and neurocognitive functioning in patients with long-standing type 1 diabetes with and without microvascular complications: a magnetoencephalography study
    Eelco van Duinkerken
    Department of Medical Psychology and Endocrinology, VU University Medical Center, Amsterdam, The Netherlands
    Diabetes 58:2335-43. 2009
    ..This study addresses functional connectivity and cognition in type 1 diabetic patients with and without proliferative retinopathy, relative to healthy control subjects, using magnetoencephalography...
  20. ncbi request reprint Usefulness of longitudinal measurements of beta-amyloid1-42 in cerebrospinal fluid of patients with various cognitive and neurologic disorders
    Femke H Bouwman
    Clin Chem 52:1604-6. 2006